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Unhealthy drug use ranges from use that risks health harms through severe drug use dis-
orders. This narrative review addresses whether screening and brief intervention (SBI),
efficacious for risky alcohol use, has efficacy for reducing other drug use and conse-
quences. Brief intervention among those seeking help shows some promise. Screening
tools have been validated though most are neither brief nor simple enough for use in gen-
eral health settings. Several randomized trials have tested the efficacy of brief intervention
for unhealthy drug use identified by screening in general health settings (i.e., in people not
seeking help for their drug use). Substantial evidence now suggests that efficacy is limited
or non-existent. Reasons likely include a range of actual and perceived severity (or lack of
severity), concomitant unhealthy alcohol use and comorbid mental health conditions, and
the wide range of types of unhealthy drug use (e.g., from marijuana, to prescription drugs,
to heroin). Although brief intervention may have some efficacy for unhealthy drug users
seeking help, the model of SBI that has effects in primary care settings on risky alcohol
use may not be efficacious for other drug use.
Keywords: screening and brief intervention, unhealthy drug use, illicit drug, efficacy, randomized trials, counseling,
identification, primary care
INTRODUCTION
Screening and brief intervention (SBI) for unhealthy alcohol use
in primary care is among the most effective and cost-effective of
preventive services (1). Unhealthy alcohol use is the target and
is defined as the spectrum from use that increases the risk for
health consequences through a diagnosable alcohol use disorder
(2). No randomized trials have compared SBI to no SBI for alco-
hol. Numerous studies in primary care find efficacy for BI vs. no
BI among patients identified by screening for modest reductions
in self-reported alcohol consumption (3). Although efficacy has
yet to be demonstrated for moderate to severe alcohol use dis-
orders (also known as dependence) (4–6), the conceptual model
includes referral to specialty treatment as one of the goals of brief
intervention for those with more severe conditions.
Brief counseling has also been applied to other health behav-
iors, such as medication adherence, nutrition, tobacco use, and
physical activity with some success (7). Since the principles may
be the same regardless of the health behavior there has been
optimism that SBI will have efficacy for other drugs. Unhealthy
drug use is defined as use of illicit drugs or potentially addic-
tive medications more than prescribed or without a prescription.
The US government has spent approximately half a billion dollars
in the past decade on clinical programs to screen and provide
brief intervention for alcohol and other drugs (8). Given the
impact of drug use on health and the need to address drug use
in general health settings, knowing whether SBI has efficacy for
preventing or reducing drug use and consequences takes on great
importance.
Observational studies have suggested possible effectiveness of
drug SBI. For example, Madras et al. (9) conducted a before/after
study and 6 months after screening found a 68% decrease in self-
reported drug use and improvements in overall health, employ-
ment, criminal justice involvement, and housing status. The effect
size is much larger than any ever seen in a randomized trial of
a similar intervention and is not plausibly attributable to SBI. A
well-done observational study with matched controls found that
exposure to SBI in the emergency department was associated with
subsequent linkage to specialty addiction treatment (10). How-
ever, one must interpret these studies with great caution and not
take them as evidence for efficacy because there are many expla-
nations for decreased use besides SBI, such as regression to the
mean, assessment reactivity, secular trends and natural history,
self-change, and others.
EFFICACY OF BRIEF INTERVENTION FOR DRUG USE
Randomized trials of brief intervention in people seeking help
can suggest possible efficacy, but they should not be taken as evi-
dence for SBI in unselected patients identified by screening. In a
meta-analysis that included interventions some consider longer
than brief (e.g., 1–2 h, often multi-session), drug BI had an effect
size of 0.29 in studies of motivational interviewing (11). In stud-
ies of treatment-seeking people, motivational interventions have
often had efficacy (12–19), though at least one high-quality study
found no efficacy (20). Several studies have found benefit in a
focused area – reducing prescriptions for benzodiazepines (21–
23). BI studies in special populations have had mixed results (24).
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A computerized intervention and voucher decreased use of drugs,
except marijuana, in postpartum women (25). A single feedback
session decreased drug (though not alcohol or marijuana) use
in homeless adolescents (26). Another study at youth agencies
found no effect on ecstasy or cocaine use (27). But other studies
have found some effects in youth in mandated treatment and high
schools (28–30).
EFFICACY OF SBI FOR DRUG USE IN GENERAL HEALTH
SETTINGS
Most people who use drugs and/or have drug use disorders neither
seek nor receive treatment (31). As a result, interventions with the
greatest potential to affect health in this area must have efficacy in
general health settings, especially in primary and preventive care
settings. Patients who receive these interventions should include
those identified by screening, not only those who seek help for
these conditions specifically. The US Preventive Services Task
Force, a leading agency that rates and recommends preventive
services based on the best evidence in the literature, reflects this
view (32).
Few studies have tested the efficacy of SBI in general health set-
tings compared with no-intervention control groups, and results
are largely disappointing (see Table 1). Key issues are that to draw
valid conclusions, adequate follow-up rates are needed, biological
testing should confirm self-reports, and outcomes beyond use are
of importance. These issues are also relevant to alcohol SBI and
although numerous studies with self-report outcome in primary
care for unhealthy alcohol use have confirmed efficacy, few have
found effects on biological or clinical outcomes, raising questions
about whether the evidence base for alcohol SBI is sufficient to
suggest that efficacy for alcohol or other substances. One study
of drug SBI compared computer to live human brief interven-
tion for drugs in primary care and included biological outcomes.
Results were similar in both groups, with some outcomes favoring
the computer group, but drug use did not change much in either
group [three points decrease in global alcohol, smoking, and sub-
stance involvement screening test (ASSIST) score], and with no
control group, efficacy could not be determined (33).
Bernstein et al. (39) reported results of a randomized trial
among adults with cocaine or heroin use identified by screening, in
women’s health, homeless, and urgent care clinics. Most (82%) had
follow-up though one in five were excluded because they had no
evidence of drug use by hair testing at study entry. Opioid absti-
nence was 9% greater and cocaine abstinence 5% greater in the
brief intervention groups though there was no increase in receipt
of addiction treatment.
In a small randomized trial (n= 59) among adolescents in pri-
mary care in Brazil, BI reduced marijuana and ecstasy related
problems (42). In project CHAT (n= 42), teenagers with drug
use consequences who had brief intervention reported less mari-
juana use than controls (43). In three randomized controlled trials
among adolescents in the emergency department, BI decreased
recidivism related to drug consequences, increased abstinence, or
increased entry into treatment (44–46). One randomized trial in
adults using psychoactive prescription drugs in a general hospi-
tal found two counseling sessions were associated with decreased
Table 1 | Randomized trial evidence regarding drug screening and brief intervention in adult general health settingsa that include at least some
primary care patients.
Citation Intervention Result (between group
differences at follow-up)
Comment
Gelberg et al. (34) Very brief advice, video doctor,
and two booster sessions
Less frequent (4 days) drug use at 3 months;
effect larger among more severe
78% Follow-up; attention control; no
biological testing; excluded those with
likely moderate to severe disorder
Roy-Byrne et al. (35, 48) Single BI with 1 week phone
booster done by social workers
3, 6, 9, and 12 months outcomes. No significant
differences in days drug use or drug use severity
Biological testing; 87% follow-up
Saitz et al. (36, 37) Single 10–15 min health
promotion advocate/health
educator BI
45-min psychologist BI with
one booster
6-month outcomes. No differences in days drug
use or drug use severity, health-related quality of
life, emergency department or hospital utilization
or HIV risk behaviors
Biological testing; 98% follow-up
Humeniuk et al. (38) Single BI largely done by clinic
staff (some by researchers in
Brazil)
Seven points or smaller difference in drug use risk
scale with 338 points theoretical maximum at
most sites except US where control group had
greater decrease in the score
86% Follow-up; no biological testing;
excluded those likely to have moderate
to severe disorderb
Bernstein et al. (39) Single BI done by health
promotion advocate
5% Absolute risk increase in cocaine abstinence;
9% risk increase in opioid abstinence
Biological testing; 82% follow-upb
aTwo additional studies have been done exclusively in emergency department settings. One had 58% loss to follow-up and found no benefit of SBI (40). The other, a
multi-site trial, has not yet had results published (41).
bSome participants in primary care (see text for details).
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drug use though whether the use was misuse or appropriate use
for pain was not clear (47).
Perhaps the most relevant study to the question at hand is the
World Health Organization randomized trial in five countries in
731 adults reporting risky drug use (excluding those with more
severe use). Patients were recruited from sexually transmitted dis-
ease clinics, dental and walk-in clinics, and community medical
care sites. Very small differences were found favoring the BI group
on a global scale of drug use risk of uncertain clinical importance
and results at the US site were negative (point estimates favored
the control group) (38). More specifically, both groups began at a
global ASSIST score of 36; the BI group reduced to 30 while the
control group reduced to 32, a 2-point difference in a scale with a
maximum score of 338. In the US, the global score decreased by
nine points in the control group and five points in the BI group
(p= 0.11, n= 218). In India, decreases were 4 vs. 8 points, respec-
tively (p=< 0.005, n= 177); Brazil 2 vs. 7 (p< 0.005, n= 165);
and in Australia 0 vs. 8 (p< 0.001, n= 170).
Several recent studies provide information on the efficacy of
SBI for drugs. Saitz et al. tested the efficacy of SBI for drugs ran-
domizing 528 primary care patients identified by screening to one
of two brief motivational interventions delivered by trained health
educators or psychologists, the latter of which included a booster
session (36, 37). At 6 months with 98% follow-up, there were no
significant differences in drug use outcomes overall or in analyses
stratified by drug type or drug use severity. This study used hair
testing to corroborate self-report. Gelberg et al. have preliminar-
ily reported a randomized trial of drug SBI in primary care, with
78% 3-month follow-up (34) (registered at www.clinicaltrials.gov
NCT01942876). Patients with more severe risky use were excluded.
The intervention was <5 min of brief advice, then a video doc-
tor, and two follow-up counseling sessions. Results were a greater
reduction in drug use days (by four) in the intervention vs. the
control group, particularly among those who used drugs more fre-
quently. Validity concerns include the absence of laboratory testing
to corroborate outcomes, which leaves social desirability bias as a
likely explanation for the results (given the largely negative find-
ings in trials with biological outcomes and large changes in drug
use in observational studies). In addition, the intervention was not
particularly brief as it included several repeat contacts (and those
with two or more such contacts had better outcomes).
Another large study in primary care also in the US has been
published (35, 48), and outcomes were verified by laboratory test-
ing. Roy-Byrne et al. (48) randomized 868 adults identified by
screening to a single brief motivational intervention and a 10-min
booster at 2 weeks by phone. At follow-up (≥87% at 3, 6, and
12 months), there were no significant differences in frequency of
use or in drug use severity.
Although not in primary care, a large randomized trial of SBI
in emergency department patients found no differences in drug
use outcomes, though 58% of participants were lost to follow-up,
substantially limiting the ability to draw firm conclusions from
the results (40). A large multi-site study of SBI in emergency
departments in the US with a minimal screening control group
and a no-intervention control group is also underway (41). Both
of these emergency department studies used biological testing to
corroborate self-report outcomes.
CONCLUSION AND IMPLICATIONS
There is little evidence that SBI for drugs other than alcohol and
tobacco will have efficacy in adult primary care settings. Three
trials have been done exclusively in primary care. One with 98%
follow-up of a large sample and biologically corroborated out-
comes is entirely negative. Another with 87% follow-up and bio-
logically corroborated outcomes also found no effects. Another
trial, smaller and with short-term and substantially lower follow-
up, has positive findings but no biological outcome confirmation.
A large multi-site emergency department study is as yet unpub-
lished. A single site study was negative and substantially limited
methodologically. A study in mixed settings including urgent care
did find small reductions in heroin and cocaine use corroborated
by biological outcomes. A hospital study of prescription drug use
was difficult to interpret. The WHO multi-site study found results
of questionable clinical importance that were inconsistent across
country (and negative in the US). In general, these results do not
support the hypothesis that SBI has efficacy for drug use.
This narrative review may have some limitations. It is a nar-
rative review based on searching Google scholar for randomized
trials of drug SBI, attendance at national and international meet-
ings where such research is likely to be presented, review of studies
funded by the National Institute on Drug Abuse (nihreporter.gov)
and search of the clinical trials.gov registry, and by review of a cur-
rent systematic review that has full methodology published (49).
While not a full systematic review, it is very unlikely that an impor-
tant clinical trial of drug use SBI has been missed though that is a
possibility.
If health behaviors are similar, why might SBI not have efficacy
for drug use? Drug use may well be different from other health
behaviors and from risky alcohol use specifically. First of all, drug
use is often illegal and socially proscribed. As a result, when it is
addressed in a health setting, the patient is using drugs despite
this social sanction, whereas for a number of other health behav-
iors that respond to brief interventions, the patient’s behavior may
be normative; when they realize their personal risks they decide to
make changes. Most people who use drugs are aware of some risks.
Drug use may be more severe than some other health behaviors.
Drug use could range from occasional marijuana use (perceived
by patients as safe) to prescription opioid misuse (a very com-
plex problem that often involves chronic difficult to treat pain), to
injection heroin or cocaine use. It seems unlikely that single brief
counseling sessions could adequately address this range, even if the
goal is to link patients to further and more specialized treatment.
Future research should always include biological outcomes.
New approaches might address multiple risk behaviors and involve
prioritizing them for intervention. Such approaches might then
focus on subgroups of patients, such as those with prescription
drug misuse or marijuana use. New approaches will also very likely
need to test multi-contact longitudinal interventions of the type
known to be more efficacious for alcohol.
For clinicians, the absence of efficacy of drug SBI does not mean
that identifying and addressing drug use in patients is not impor-
tant. It simply means that doing so by screening using validated
tools to detect unhealthy use may not immediately lead to reduced
drug use and problems after a brief intervention. Patients with
symptoms need to be asked about drug use just as they would
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be asked about medication use, use of complementary therapies
(e.g., herbal treatments), and dietary habits. Such information is
critical both to appropriate diagnosis of medical and psychiatric
conditions and to safe prescribing, particularly of psychoactive
and addictive medications.
The evidence for efficacy of drug SBI is lacking. Editorial-
ists, leaders at the US National Institute on Drug Abuse and the
National Institute on Alcohol Abuse and Alcoholism, the largest
supporters of substance use research in the world, say it is time
to “go back to the drawing board” regarding screening and BI for
drugs in primary care (50). Clinicians need to address drug use
but cannot rely on SBI, a seemingly simple solution, to solve what
is, in fact, a complex problem. Researchers need to find more effec-
tive means in general health settings to address what is a common
preventable cause of death in the world.
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